Johnson & Johnson (JNJ) 100.91 $JNJ
Johnson & Johnson Is Rewarding but Too Expensive
at The Street - 6 mins ago
The share price may be too high for yield-hungry investors. But that could be changing soon.
Refractory Multiple Myeloma - Pipeline Review, H1 2014: 33 Companies and 48 Drugs Profiled
M2 - 33 mins ago
Research and Markets (http://www.researchandmarkets.com/research/r636v2/refractory) has announced the addition of the "Refractory Multiple Myeloma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Multiple Myeloma and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Refractory Multiple Myeloma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Refractory Multiple Myeloma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Refractory Multiple Myeloma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved: - AbbVie Inc. - Acceleron Pharma, Inc. - Acetylon Pharmaceuticals, Inc. - Altor BioScience Corporation - Array BioPharma Inc. - Astellas Pharma Inc. - Bristol-Myers Squibb Company - Celgene Corporation - Eli Lilly and Company - Exelixis, Inc. - Genentech, Inc. - GlaxoSmithKline plc - Incyte Corporation - Janssen Biotech, Inc. - Johnson & Johnson - Kyowa Hakko Kirin Co., Ltd. - Millennium Pharmaceuticals, Inc. - MorphoSys AG - Novartis AG - Oncolytics Biotech Inc. - Oncopeptides AB - Onyx Pharmaceuticals, Inc. - Pfizer Inc. - Pharma Mar, S.A. - Pharmacyclics, Inc. - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Sanofi - Senesco Technologies, Inc. - Senhwa Biosciences Drug Profiles: - ixazomib citrate - panobinostat - carfilzomib - elotuzumab - plitidepsin - bendamustine - ibrutinib - ruxolitinib phosphate - ARRY-520 - ALT-801 - pomalidomide - chloroquine [bortezomib] [cyclophosphamide] - Melflufen - Circularly Permuted TRAIL - alisertib - daratumumab - PRLX-93936 - carfilzomib - cabozantinib (s)-malate - SNS-01T - SL-401 - TH-302 - P-276 - MOR-202 - KW-2478 - palbociclib - luminespib - plerixafor - ricolinostat - LY-2812176 For more information visit http://www.researchandmarkets.com/research/r636v2/refractory
Tuberculosis - Pipeline Review, H1 2014: 54 Companies and 141 Drugs Profiled
M2 - 49 mins ago
Research and Markets (http://www.researchandmarkets.com/research/gtc5l6/tuberculosis) has announced the addition of the "Tuberculosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Tuberculosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tuberculosis and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Tuberculosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Tuberculosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Tuberculosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved: - Abera Bioscience AB - Achillion Pharmaceuticals, Inc. - Anacor Pharmaceuticals, Inc. - Archivel Farma S.L. - AstraZeneca PLC - B&C Biopharm - BioDiem Ltd - Bioversys AG - Canopus BioPharma Incorporated - Cellceutix Corporation - Chimerix, Inc. - Chongqing Zhifei Biological Products Co., Ltd. - Crucell N.V. - Dafra Pharma International Ltd. - Eisai Co., Ltd. - Eli Lilly and Company - Ensoltek Co., Ltd. - EpiVax, Inc. - FIT Biotech Oyj - Genticel - GlaxoSmithKline plc - GlobalAcorn - Globeimmune, Inc. - Imaxio - Immunitor, Inc. - ImmunoBiology Ltd. - Immunovaccine, Inc. - Johnson & Johnson - Lipotek Pty Ltd. - Medisyn Technologies, Inc. Drug Profiles: - delamanid - delamanid - V-7 Vaccine - SQ-109 - delamanid - Tuberculosis Vaccine - sutezolid - VPM-1002 - GSK-692342 - Crucell Ad-35 - RUTI Vaccine - SSI H56-IC31 Vaccine - AERAS-422 Vaccine - IMX-313-TB - Ad5Ag85A Vaccine - PMX-10072 - NasL3/HtkBCG Vaccine - MTBVAC01 - Ac2SGL Diacylated Sulfoglycolipid Vaccine - HG-85A/B - HG856-A - HG856-BCG - R32Kda-BCG Vaccine - AERAS-Capsid Vaccine - HBHA Vaccine - Streptomyces Live Vector Vaccine - rBCG(mbtB)30 Vaccine - NasL3/AM85B Vaccine - paBCG Vaccine - ORT-VAC DNA Vaccine For more information visit http://www.researchandmarkets.com/research/gt...berculosis
Bone Metastasis - Pipeline Review, H1 2014: 20 Companies and 33 Drugs Profiled
M2 - 1 hr 49 mins ago
Research and Markets (http://www.researchandmarkets.com/research/7v66kz/bone_metastasis) has announced the addition of the "Bone Metastasis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Metastasis and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Bone Metastasis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Bone Metastasis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Bone Metastasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects Companies Involved: - APT Therapeutics, Inc. - Alethia Biotherapeutics Inc. - AlphaMab Co., Ltd - Amgen Inc. - Amura Holdings Ltd. - Bayer AG - Celsion Corporation - Debiopharm International S.A. - Deciphera Pharmaceuticals, LLC - DexTech Medical AB - Digna Biotech, S.L. - Eli Lilly and Company - Johnson & Johnson - Medivir AB - Merrion Pharmaceuticals Plc - Osteologix Holdings Plc. - Sigma-Tau S.p.A. - TWi Pharmaceuticals, Inc. - Takeda Pharmaceutical Company Limited - Transgene SA Drug Profiles: - denosumab - denosumab - radium Ra 223 dichloride - zoledronic acid - MLN-1202 - doxorubicin liposomal - radium Ra 223 dichloride - Osteodex - MIV-711 - Debio-0719 - P-17 - disitertide - MIV-710 - SST-0001 - TG-3003 - AB-25E9 - AM-3701 - DCC-2909 - AC-301 - APT-102 - Secreted Phosphoprotein 24 KDa - Vicrostatin - ADM-01 - JNJ-28312141 - DP-6865 - LY-2109761 - LY-364937 - EGFR Inhibitors for Oncology - (paclitaxel PEG alendronate) For more information visit http://www.researchandmarkets.com/research/7v...metastasis
Diabetic Nephropathy - Pipeline Review, H1 2014: 37 Companies and 58 Drugs Profiled
M2 - 2 hrs 6 mins ago
Research and Markets (http://www.researchandmarkets.com/research/x6n63h/diabetic) has announced the addition of the "Diabetic Nephropathy - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Nephropathy and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diabetic Nephropathy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Diabetic Nephropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved: - AbbVie Inc. - Ampio Pharmaceuticals, Inc. - Angelini Group - Astellas Pharma Inc. - Bayer AG - CCRP Therapeutics GmbH - ChemoCentryx, Inc. - Chong Kun Dang Pharmaceutical Corp. - Concert Pharmaceuticals, Inc. - Cyano Biotech GmbH - Daiichi Sankyo Company, Limited - Dongwha Pharm Co., Ltd. - Eli Lilly and Company - Emergent BioSolutions Inc. - Fibrotech Therapeutics Pty. Ltd. - GNI Group Ltd. - Galectin Therapeutics - GenKyoTex S.A. - Gentium S.p.A. - Glucox Biotech AB - IMMD Inc. - Intercept Pharmaceuticals, Inc. - Inventiva SAS - Johnson & Johnson - Mesoblast Limited - Mitsubishi Pharmaceutical Corporation - Mitsubishi Tanabe Pharma Corporation - NephroGenex, Inc. - Noxxon Pharma AG Drug Profiles: - canagliflozin - atrasentan hydrochloride - baricitinib - NOX-E-36 - IMD-1041 - CS-3150 - DW-1029M - GKT-137831 - PF-00489791 - CCX-140 - LY-2382770 - bindarit - Colchicine - probucol - PF-04634817 - Pyridoxamine Dihydrochloride - GLY-230 - corticotropin - CTP-499 - MT-3995 - finerenone - cilostazol - PHN-033 - CKD-322 - Allogeneic Mesenchymal Precursor Cells For Diabetic Nephropathy - LY-3016859 - FT-011 - ASP-8232 - pirfenidone - THR-123 For more information visit http://www.researchandmarkets.com/research/x6n63h/diabetic
Janssen Announces Expanded Collaboration with International Partnership for Microbicides for Development and Commercialization of Dapivirine for Prevention of Sexual Transmission of HIV
PR Newswire - 2 hrs 6 mins ago
Janssen R&D Ireland Ltd. (Janssen) today announced that it has expanded its collaboration with the International Partnership for Microbicides (IPM) for the development and delivery of dapivirine (TMC120) for the prevention of HIV. This is the latest innovative public-private partnership from the newly established Janssen Global Public Health group and a significant contribution to the wider efforts of Johnson & Johnson to improve public health worldwide.
Allergan Reports Strong Q1 While Weighing Valeant Bid
at Investor's Business Daily - Wed May 07, 5:06PM CDT
Embattled specialty drugmaker Allergan on Wednesday beat Wall Street's first-quarter earnings estimates and raised its guidance, but the company's stock slid 0.3% to close at 165.87 as its future remained in doubt. Allergan (AGN) reported earnings of...
Final Glance: Pharmaceuticals companies
AP - Wed May 07, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Final Glance: Medical Devices companies
AP - Wed May 07, 5:02PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Johnson & Johnson Set to Possibly Pullback After Yesterday's Rally of 1.41%
Comtex SmarTrend(R) - Wed May 07, 3:45PM CDT
Johnson & Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $99.35 to a high of $101.04. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $100.38 on volume of 8.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Johnson & Johnson Rises 1.41% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed May 07, 3:45PM CDT
Johnson & Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $99.35 to a high of $101.04. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $100.38 on volume of 8.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Research and Markets: Ulcerative Colitis - India Drug Forecast and Market Analysis to 2022
Business Wire - Wed May 07, 2:50PM CDT
Research and Markets (http://www.researchandmarkets.com/research/v8j89j/pharmapoint) has announced the addition of the "PharmaPoint: Ulcerative Colitis - India Drug Forecast and Market Analysis to 2022" report to their offering.
Bayer to Purchase Merck's Consumer Division - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 2:35PM CDT
Bayer (BAYRY) entered into a definitive agreement with Merck (MRK) to acquire the latter's consumer care business.
Research and Markets: PharmaPoint: Ulcerative Colitis - Canada Drug Forecast and Market Analysis to 2022
Business Wire - Wed May 07, 2:18PM CDT
Research and Markets (http://www.researchandmarkets.com/research/ll54rk/pharmapoint) has announced the addition of the "PharmaPoint: Ulcerative Colitis - Canada Drug Forecast and Market Analysis to 2022" report to their offering.
1 Company Johnson & Johnson Should Buy
Brian Nichols, The Motley Fool - Motley Fool - Wed May 07, 1:30PM CDT
After a near 60% gain in the last two years, Johnson & Johnson is trading at 19 times trailing earnings, which compared to other big pharma peers is likely fair value. Therefore, finding value from this point is going to become more difficult,...
Allergan Beats on Earnings, Guidance Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 12:50PM CDT
Allergan, Inc. (AGN) reported first quarter 2014 earnings of $1.18 per share.
Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2014: 79 Companies Profiled
M2 - Wed May 07, 12:21PM CDT
Research and Markets (http://www.researchandmarkets.com/research/2d32kc/type_1_diabetes) has announced the addition of the "Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Type 1 Diabetes (Juvenile Diabetes), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Alcon, Inc. - Johnson & Johnson - Boehringer Ingelheim GmbH - Osiris Therapeutics, Inc. - Sanofi - AstraZeneca PLC - Eli Lilly and Company - Inovio Pharmaceuticals, Inc. - MedImmune, LLC - Daiichi Sankyo Company, Limited - Merck & Co., Inc. - AbGenomics International, Inc. - Novo Nordisk A/S - Generex Biotechnology Corporation - BioLineRx, Ltd. - Kissei Pharmaceutical Co., Ltd. - Pfizer Inc. - Cell Therapeutics, Inc. - Hadasit Medical Research Services & Development Ltd - Biodel Inc. - MannKind Corporation - Halozyme Therapeutics, Inc. - Merck KGaA - Evotec AG - Karo Bio AB - Ligand Pharmaceuticals, Inc. - Opexa Therapeutics, Inc. - Compugen Ltd. - Oramed Pharmaceuticals, Inc. - Lexicon Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/2d...1_diabetes
Midday Glance: Medical Devices companies
AP - Wed May 07, 12:18PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Midday Glance: Pharmaceuticals companies
AP - Wed May 07, 12:18PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Uceris (Ulcerative Colitis) - Forecast and Market Analysis to 2022
M2 - Wed May 07, 11:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2b36jp/uceris) has announced the addition of the "Uceris (Ulcerative Colitis) - Forecast and Market Analysis to 2022" report to their offering. During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson's (J&J's) Simponi and Takeda's Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively. Uceris is a synthetic steroid of the glucocorticosteroid family that is indicated for mild-to-moderate UC. It is formulated as a slow-release foam that is administered rectally. Uceris binds to glucocorticoid receptors and causes suppression of endogenous cortisol concentrations and impairment of the hypothalamus-pituitary-adrenal (HPA) axis function. Budesonide has mainly anti-inflammatory activity, and due to an extended first-pass effect, Uceris has less systemic absorption than other corticosteroids. Scope - Overview of Ulcerative Colitis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Uceris including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Uceris for the top seven countries from 2012 to 2022. - Sales information covered for the US, France, Germany, Italy, Spain, the UK and Canada. Key Topics Covered: 1 Table of Contents 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Uceris (budesonide) 7 Appendix For more information visit http://www.researchandmarkets.com/research/2b36jp/uceris
Johnson & Johnson Is Rewarding but Too Expensive
at The Street - 6 mins ago
The share price may be too high for yield-hungry investors. But that could be changing soon.
Refractory Multiple Myeloma - Pipeline Review, H1 2014: 33 Companies and 48 Drugs Profiled
M2 - 33 mins ago
Research and Markets (http://www.researchandmarkets.com/research/r636v2/refractory) has announced the addition of the "Refractory Multiple Myeloma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Multiple Myeloma and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Refractory Multiple Myeloma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Refractory Multiple Myeloma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Refractory Multiple Myeloma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved: - AbbVie Inc. - Acceleron Pharma, Inc. - Acetylon Pharmaceuticals, Inc. - Altor BioScience Corporation - Array BioPharma Inc. - Astellas Pharma Inc. - Bristol-Myers Squibb Company - Celgene Corporation - Eli Lilly and Company - Exelixis, Inc. - Genentech, Inc. - GlaxoSmithKline plc - Incyte Corporation - Janssen Biotech, Inc. - Johnson & Johnson - Kyowa Hakko Kirin Co., Ltd. - Millennium Pharmaceuticals, Inc. - MorphoSys AG - Novartis AG - Oncolytics Biotech Inc. - Oncopeptides AB - Onyx Pharmaceuticals, Inc. - Pfizer Inc. - Pharma Mar, S.A. - Pharmacyclics, Inc. - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Sanofi - Senesco Technologies, Inc. - Senhwa Biosciences Drug Profiles: - ixazomib citrate - panobinostat - carfilzomib - elotuzumab - plitidepsin - bendamustine - ibrutinib - ruxolitinib phosphate - ARRY-520 - ALT-801 - pomalidomide - chloroquine [bortezomib] [cyclophosphamide] - Melflufen - Circularly Permuted TRAIL - alisertib - daratumumab - PRLX-93936 - carfilzomib - cabozantinib (s)-malate - SNS-01T - SL-401 - TH-302 - P-276 - MOR-202 - KW-2478 - palbociclib - luminespib - plerixafor - ricolinostat - LY-2812176 For more information visit http://www.researchandmarkets.com/research/r636v2/refractory
Tuberculosis - Pipeline Review, H1 2014: 54 Companies and 141 Drugs Profiled
M2 - 49 mins ago
Research and Markets (http://www.researchandmarkets.com/research/gtc5l6/tuberculosis) has announced the addition of the "Tuberculosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Tuberculosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tuberculosis and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Tuberculosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Tuberculosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Tuberculosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved: - Abera Bioscience AB - Achillion Pharmaceuticals, Inc. - Anacor Pharmaceuticals, Inc. - Archivel Farma S.L. - AstraZeneca PLC - B&C Biopharm - BioDiem Ltd - Bioversys AG - Canopus BioPharma Incorporated - Cellceutix Corporation - Chimerix, Inc. - Chongqing Zhifei Biological Products Co., Ltd. - Crucell N.V. - Dafra Pharma International Ltd. - Eisai Co., Ltd. - Eli Lilly and Company - Ensoltek Co., Ltd. - EpiVax, Inc. - FIT Biotech Oyj - Genticel - GlaxoSmithKline plc - GlobalAcorn - Globeimmune, Inc. - Imaxio - Immunitor, Inc. - ImmunoBiology Ltd. - Immunovaccine, Inc. - Johnson & Johnson - Lipotek Pty Ltd. - Medisyn Technologies, Inc. Drug Profiles: - delamanid - delamanid - V-7 Vaccine - SQ-109 - delamanid - Tuberculosis Vaccine - sutezolid - VPM-1002 - GSK-692342 - Crucell Ad-35 - RUTI Vaccine - SSI H56-IC31 Vaccine - AERAS-422 Vaccine - IMX-313-TB - Ad5Ag85A Vaccine - PMX-10072 - NasL3/HtkBCG Vaccine - MTBVAC01 - Ac2SGL Diacylated Sulfoglycolipid Vaccine - HG-85A/B - HG856-A - HG856-BCG - R32Kda-BCG Vaccine - AERAS-Capsid Vaccine - HBHA Vaccine - Streptomyces Live Vector Vaccine - rBCG(mbtB)30 Vaccine - NasL3/AM85B Vaccine - paBCG Vaccine - ORT-VAC DNA Vaccine For more information visit http://www.researchandmarkets.com/research/gt...berculosis
Bone Metastasis - Pipeline Review, H1 2014: 20 Companies and 33 Drugs Profiled
M2 - 1 hr 49 mins ago
Research and Markets (http://www.researchandmarkets.com/research/7v66kz/bone_metastasis) has announced the addition of the "Bone Metastasis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Metastasis and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Bone Metastasis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Bone Metastasis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Bone Metastasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects Companies Involved: - APT Therapeutics, Inc. - Alethia Biotherapeutics Inc. - AlphaMab Co., Ltd - Amgen Inc. - Amura Holdings Ltd. - Bayer AG - Celsion Corporation - Debiopharm International S.A. - Deciphera Pharmaceuticals, LLC - DexTech Medical AB - Digna Biotech, S.L. - Eli Lilly and Company - Johnson & Johnson - Medivir AB - Merrion Pharmaceuticals Plc - Osteologix Holdings Plc. - Sigma-Tau S.p.A. - TWi Pharmaceuticals, Inc. - Takeda Pharmaceutical Company Limited - Transgene SA Drug Profiles: - denosumab - denosumab - radium Ra 223 dichloride - zoledronic acid - MLN-1202 - doxorubicin liposomal - radium Ra 223 dichloride - Osteodex - MIV-711 - Debio-0719 - P-17 - disitertide - MIV-710 - SST-0001 - TG-3003 - AB-25E9 - AM-3701 - DCC-2909 - AC-301 - APT-102 - Secreted Phosphoprotein 24 KDa - Vicrostatin - ADM-01 - JNJ-28312141 - DP-6865 - LY-2109761 - LY-364937 - EGFR Inhibitors for Oncology - (paclitaxel PEG alendronate) For more information visit http://www.researchandmarkets.com/research/7v...metastasis
Diabetic Nephropathy - Pipeline Review, H1 2014: 37 Companies and 58 Drugs Profiled
M2 - 2 hrs 6 mins ago
Research and Markets (http://www.researchandmarkets.com/research/x6n63h/diabetic) has announced the addition of the "Diabetic Nephropathy - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Nephropathy and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diabetic Nephropathy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Diabetic Nephropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved: - AbbVie Inc. - Ampio Pharmaceuticals, Inc. - Angelini Group - Astellas Pharma Inc. - Bayer AG - CCRP Therapeutics GmbH - ChemoCentryx, Inc. - Chong Kun Dang Pharmaceutical Corp. - Concert Pharmaceuticals, Inc. - Cyano Biotech GmbH - Daiichi Sankyo Company, Limited - Dongwha Pharm Co., Ltd. - Eli Lilly and Company - Emergent BioSolutions Inc. - Fibrotech Therapeutics Pty. Ltd. - GNI Group Ltd. - Galectin Therapeutics - GenKyoTex S.A. - Gentium S.p.A. - Glucox Biotech AB - IMMD Inc. - Intercept Pharmaceuticals, Inc. - Inventiva SAS - Johnson & Johnson - Mesoblast Limited - Mitsubishi Pharmaceutical Corporation - Mitsubishi Tanabe Pharma Corporation - NephroGenex, Inc. - Noxxon Pharma AG Drug Profiles: - canagliflozin - atrasentan hydrochloride - baricitinib - NOX-E-36 - IMD-1041 - CS-3150 - DW-1029M - GKT-137831 - PF-00489791 - CCX-140 - LY-2382770 - bindarit - Colchicine - probucol - PF-04634817 - Pyridoxamine Dihydrochloride - GLY-230 - corticotropin - CTP-499 - MT-3995 - finerenone - cilostazol - PHN-033 - CKD-322 - Allogeneic Mesenchymal Precursor Cells For Diabetic Nephropathy - LY-3016859 - FT-011 - ASP-8232 - pirfenidone - THR-123 For more information visit http://www.researchandmarkets.com/research/x6n63h/diabetic
Janssen Announces Expanded Collaboration with International Partnership for Microbicides for Development and Commercialization of Dapivirine for Prevention of Sexual Transmission of HIV
PR Newswire - 2 hrs 6 mins ago
Janssen R&D Ireland Ltd. (Janssen) today announced that it has expanded its collaboration with the International Partnership for Microbicides (IPM) for the development and delivery of dapivirine (TMC120) for the prevention of HIV. This is the latest innovative public-private partnership from the newly established Janssen Global Public Health group and a significant contribution to the wider efforts of Johnson & Johnson to improve public health worldwide.
Allergan Reports Strong Q1 While Weighing Valeant Bid
at Investor's Business Daily - Wed May 07, 5:06PM CDT
Embattled specialty drugmaker Allergan on Wednesday beat Wall Street's first-quarter earnings estimates and raised its guidance, but the company's stock slid 0.3% to close at 165.87 as its future remained in doubt. Allergan (AGN) reported earnings of...
Final Glance: Pharmaceuticals companies
AP - Wed May 07, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Final Glance: Medical Devices companies
AP - Wed May 07, 5:02PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Johnson & Johnson Set to Possibly Pullback After Yesterday's Rally of 1.41%
Comtex SmarTrend(R) - Wed May 07, 3:45PM CDT
Johnson & Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $99.35 to a high of $101.04. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $100.38 on volume of 8.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Johnson & Johnson Rises 1.41% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed May 07, 3:45PM CDT
Johnson & Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $99.35 to a high of $101.04. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $100.38 on volume of 8.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Research and Markets: Ulcerative Colitis - India Drug Forecast and Market Analysis to 2022
Business Wire - Wed May 07, 2:50PM CDT
Research and Markets (http://www.researchandmarkets.com/research/v8j89j/pharmapoint) has announced the addition of the "PharmaPoint: Ulcerative Colitis - India Drug Forecast and Market Analysis to 2022" report to their offering.
Bayer to Purchase Merck's Consumer Division - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 2:35PM CDT
Bayer (BAYRY) entered into a definitive agreement with Merck (MRK) to acquire the latter's consumer care business.
Research and Markets: PharmaPoint: Ulcerative Colitis - Canada Drug Forecast and Market Analysis to 2022
Business Wire - Wed May 07, 2:18PM CDT
Research and Markets (http://www.researchandmarkets.com/research/ll54rk/pharmapoint) has announced the addition of the "PharmaPoint: Ulcerative Colitis - Canada Drug Forecast and Market Analysis to 2022" report to their offering.
1 Company Johnson & Johnson Should Buy
Brian Nichols, The Motley Fool - Motley Fool - Wed May 07, 1:30PM CDT
After a near 60% gain in the last two years, Johnson & Johnson is trading at 19 times trailing earnings, which compared to other big pharma peers is likely fair value. Therefore, finding value from this point is going to become more difficult,...
Allergan Beats on Earnings, Guidance Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 12:50PM CDT
Allergan, Inc. (AGN) reported first quarter 2014 earnings of $1.18 per share.
Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2014: 79 Companies Profiled
M2 - Wed May 07, 12:21PM CDT
Research and Markets (http://www.researchandmarkets.com/research/2d32kc/type_1_diabetes) has announced the addition of the "Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Type 1 Diabetes (Juvenile Diabetes), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Alcon, Inc. - Johnson & Johnson - Boehringer Ingelheim GmbH - Osiris Therapeutics, Inc. - Sanofi - AstraZeneca PLC - Eli Lilly and Company - Inovio Pharmaceuticals, Inc. - MedImmune, LLC - Daiichi Sankyo Company, Limited - Merck & Co., Inc. - AbGenomics International, Inc. - Novo Nordisk A/S - Generex Biotechnology Corporation - BioLineRx, Ltd. - Kissei Pharmaceutical Co., Ltd. - Pfizer Inc. - Cell Therapeutics, Inc. - Hadasit Medical Research Services & Development Ltd - Biodel Inc. - MannKind Corporation - Halozyme Therapeutics, Inc. - Merck KGaA - Evotec AG - Karo Bio AB - Ligand Pharmaceuticals, Inc. - Opexa Therapeutics, Inc. - Compugen Ltd. - Oramed Pharmaceuticals, Inc. - Lexicon Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/2d...1_diabetes
Midday Glance: Medical Devices companies
AP - Wed May 07, 12:18PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Midday Glance: Pharmaceuticals companies
AP - Wed May 07, 12:18PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Uceris (Ulcerative Colitis) - Forecast and Market Analysis to 2022
M2 - Wed May 07, 11:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2b36jp/uceris) has announced the addition of the "Uceris (Ulcerative Colitis) - Forecast and Market Analysis to 2022" report to their offering. During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson's (J&J's) Simponi and Takeda's Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively. Uceris is a synthetic steroid of the glucocorticosteroid family that is indicated for mild-to-moderate UC. It is formulated as a slow-release foam that is administered rectally. Uceris binds to glucocorticoid receptors and causes suppression of endogenous cortisol concentrations and impairment of the hypothalamus-pituitary-adrenal (HPA) axis function. Budesonide has mainly anti-inflammatory activity, and due to an extended first-pass effect, Uceris has less systemic absorption than other corticosteroids. Scope - Overview of Ulcerative Colitis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Uceris including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Uceris for the top seven countries from 2012 to 2022. - Sales information covered for the US, France, Germany, Italy, Spain, the UK and Canada. Key Topics Covered: 1 Table of Contents 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Uceris (budesonide) 7 Appendix For more information visit http://www.researchandmarkets.com/research/2b36jp/uceris
